Evidence map›Paper›PMID 26147510›Full record

ArticlePloS one2015

Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis.

Alexandre Henriques, Hélène Blasco, Marie-Céline Fleury, Philippe Corcia, Andoni Echaniz-Laguna, Laura Robelin, Gabrielle Rudolf, Thiebault Lequeu, Martine Bergaentzle, Christian Gachet and 6 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alexandre HenriquesINSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénerescence, Strasbourg, France; Université de Strasbourg, UMR_S1118, Fédération de Médecine Translationnelle, Strasbourg, France.
Hélène BlascoINSERM, Université François-Rabelais, U930, Neurogénétique et Neurométabolomique, Tours, France; CHRU de Tours, Laboratoire de Biochimie et de Biologie Moléculaire, Tours, France.
Marie-Céline FleuryHôpitaux Universitaires de Strasbourg, Service de Neurologie, Fédération de Médecine Transrationnelle, Strasbourg, France.
Philippe CorciaINSERM, Université François-Rabelais, U930, Neurogénétique et Neurométabolomique, Tours, France; CHRU de Tours, Centre SLA, Tours, France.
Andoni Echaniz-LagunaINSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénerescence, Strasbourg, France; Université de Strasbourg, UMR_S1118, Fédération de Médecine Translationnelle, Strasbourg, France; Hôpitaux Universitaires de Strasbourg, Service de Neurologie, Fédération de Médecine Transrationnelle, Strasbourg, France.
Laura RobelinINSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénerescence, Strasbourg, France; Université de Strasbourg, UMR_S1118, Fédération de Médecine Translationnelle, Strasbourg, France.
Gabrielle RudolfHôpitaux Universitaires de Strasbourg, Service de Neurologie, Fédération de Médecine Transrationnelle, Strasbourg, France.
Thiebault LequeuINSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénerescence, Strasbourg, France; Université de Strasbourg, UMR_S1118, Fédération de Médecine Translationnelle, Strasbourg, France.
Martine BergaentzleUniversité de Strasbourg, IPHC, Equipe de Chimie Analytique des Molécules BioActives, Illkirch-Graffenstaden, France; CNRS, UMR 7178, Strasbourg, France.
Christian GachetINSERM, Université de Strasbourg, UMR_S949, Etablissement Français du Sang - Alsace, Strasbourg, France.
Pierre-François PradatAssistance Publique - Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Fédération des Maladies du Système Nerveux, Centre Référent Maladie Rare SLA, Paris, France.
Eric MarchioniUniversité de Strasbourg, IPHC, Equipe de Chimie Analytique des Molécules BioActives, Illkirch-Graffenstaden, France; CNRS, UMR 7178, Strasbourg, France.
Christian R AndresINSERM, Université François-Rabelais, U930, Neurogénétique et Neurométabolomique, Tours, France; CHRU de Tours, Laboratoire de Biochimie et de Biologie Moléculaire, Tours, France.
Christine TranchantHôpitaux Universitaires de Strasbourg, Service de Neurologie, Fédération de Médecine Transrationnelle, Strasbourg, France.
Jose-Luis Gonzalez De AguilarINSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénerescence, Strasbourg, France; Université de Strasbourg, UMR_S1118, Fédération de Médecine Translationnelle, Strasbourg, France.
Jean-Philippe LoefflerINSERM, U1118, Mécanismes Centraux et Périphériques de la Neurodégénerescence, Strasbourg, France; Université de Strasbourg, UMR_S1118, Fédération de Médecine Translationnelle, Strasbourg, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing evidence supports a link between fatty acid metabolism and amyotrophic lateral sclerosis (ALS). Here we determined the fatty acid composition of blood lipids to identify markers of disease progression and survival. We enrolled 117 patients from two clinical centers and 48 of these were age and gender matched with healthy volunteers. We extracted total lipids from serum and blood cells, and separated fatty acid methyl esters by gas chromatography. We measured circulating biochemical parameters indicative of the metabolic status. Association between fatty acid composition and clinical readouts was studied, including ALS functional rating scale-revised (ALSFRS-R), survival, disease duration, site of onset and body mass index. Palmitoleate (16:1) and oleate (18:1) levels, and stearoyl-CoA desaturase indices (16:1/16:0 and 18:1/18:0) significantly increased in blood cells from ALS patients compared to healthy controls. Palmitoleate levels and 16:1/16:0 ratio in blood cells, but not body mass index or leptin concentrations, negatively correlated with ALSFRS-R decline over a six-month period (p<0.05). Multivariate Cox analysis, with age, body mass index, site of onset and ALSFRS-R as covariables, showed that blood cell 16:1/16:0 ratio was an independent prognostic factor for survival (hazard ratio=0.1 per unit of ratio, 95% confidence interval=0.01-0.57, p=0.009). In patients with high 16:1/16:0 ratio, survival at blood collection was extended by 10 months, as compared to patients with low ratio. The 16:1/16:0 index is an easy-to-handle parameter that predicts survival of ALS patients independently of body mass index. It therefore deserves further validation in larger cohorts for being used to assess disease outcome and effects of disease-modifying drugs.

Indexed as

AdultAgedAmyotrophic Lateral SclerosisBody Mass IndexCase-Control StudiesDisease ProgressionFatty Acids, MonounsaturatedFemaleHumansLeptinMaleMiddle AgedPalmitic AcidPrognosisSeverity of Illness IndexSurvival RateFatty Acids, MonounsaturatedLeptinPalmitic Acidpalmitoleic acid

Identifiers

PMID26147510
PMCPMC4492495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.